Arrowhead Pharmaceuticals, Inc. $ARWR Shares Sold by Hudson Bay Capital Management LP

Hudson Bay Capital Management LP reduced its holdings in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 65.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 90,000 shares of the biotechnology company’s stock after selling 170,000 shares during the period. Hudson Bay Capital Management LP owned about 0.07% of Arrowhead Pharmaceuticals worth $3,104,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. iSAM Funds UK Ltd purchased a new position in shares of Arrowhead Pharmaceuticals during the third quarter worth $29,000. Virtus Advisers LLC acquired a new position in Arrowhead Pharmaceuticals during the second quarter valued at $34,000. Salomon & Ludwin LLC purchased a new stake in Arrowhead Pharmaceuticals in the third quarter valued at $34,000. Federated Hermes Inc. acquired a new stake in Arrowhead Pharmaceuticals during the 3rd quarter worth about $52,000. Finally, Smartleaf Asset Management LLC grew its position in Arrowhead Pharmaceuticals by 2,186.5% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,692 shares of the biotechnology company’s stock worth $57,000 after purchasing an additional 1,618 shares during the period. Institutional investors and hedge funds own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Price Performance

Shares of NASDAQ ARWR opened at $56.33 on Friday. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.38 and a current ratio of 3.38. The firm has a fifty day moving average of $63.57 and a 200 day moving average of $52.56. The firm has a market cap of $7.89 billion, a PE ratio of 36.82 and a beta of 1.23. Arrowhead Pharmaceuticals, Inc. has a one year low of $9.57 and a one year high of $76.76.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, February 5th. The biotechnology company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by ($0.38). The company had revenue of $264.03 million for the quarter, compared to analysts’ expectations of $225.66 million. Arrowhead Pharmaceuticals had a net margin of 18.54% and a return on equity of 35.64%. The business’s revenue for the quarter was up 10461.3% on a year-over-year basis. During the same period in the previous year, the business earned ($1.39) earnings per share. As a group, research analysts predict that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Insider Activity at Arrowhead Pharmaceuticals

In other Arrowhead Pharmaceuticals news, Director Mauro Ferrari sold 7,530 shares of the business’s stock in a transaction that occurred on Friday, December 26th. The stock was sold at an average price of $70.00, for a total transaction of $527,100.00. Following the completion of the sale, the director directly owned 69,053 shares in the company, valued at approximately $4,833,710. The trade was a 9.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Christopher Richard Anzalone sold 51,726 shares of the stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $69.13, for a total value of $3,575,818.38. Following the transaction, the chief executive officer directly owned 3,805,926 shares of the company’s stock, valued at $263,103,664.38. The trade was a 1.34% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 184,686 shares of company stock valued at $12,136,118. 3.60% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on ARWR. B. Riley Financial lifted their price objective on Arrowhead Pharmaceuticals from $61.00 to $101.00 and gave the company a “buy” rating in a research note on Thursday, January 22nd. The Goldman Sachs Group raised their target price on Arrowhead Pharmaceuticals from $50.00 to $85.00 and gave the stock a “neutral” rating in a report on Wednesday, January 7th. Chardan Capital lifted their price target on Arrowhead Pharmaceuticals from $60.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday, January 7th. Royal Bank Of Canada boosted their price target on Arrowhead Pharmaceuticals from $52.00 to $80.00 and gave the company an “outperform” rating in a report on Thursday, December 11th. Finally, Weiss Ratings upgraded Arrowhead Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a research report on Friday, February 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $81.67.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Since its founding in 2008, Arrowhead has leveraged its proprietary delivery platform—known internally as the Advanced RNAi Compound (ARC) technology—to silence disease-causing genes in patients suffering from genetically defined diseases. The company’s approach aims to offer durable, targeted treatments across a range of therapeutic areas.

The company’s pipeline includes multiple candidates in various stages of development.